On Wednesday, Shares of Palatin Technologies, Inc (NYSEMKT:PTN), gain 1.60% to $0.955, after the Food and Drug Administration approved the first drug to treat low sexual desire in women yesterday.
The FDA said that the drug, Addyi, will only be accessible through certified and specially trained health care professionals and pharmacies due to its safety issues.
“This is the biggest breakthrough in women’s sexual health since the advent of ‘the Pill’ for contraception. “It validates (and) legitimizes female sexuality as an important component of health,” The National Consumers League said in a statement, according to Reuters.
Palatin Technologies, Inc., a biopharmaceutical company, develops peptide therapeutics for the treatment of diseases. The company’s clinical development product is Bremelanotide, a peptide melanocortin receptor agonist that has accomplished Phase 2B clinical trial for the treatment of female sexual dysfunction (FSD).
Shares of Hertz Global Holdings Inc (NYSE:HTZ), inclined 0.21% to $18.89, during its last trading session, after a group of the company’s executives counting its CEO purchased 117,450 shares.
The executives purchased a total of $2.13 million worth of shares on August 13 and 14, according to Barron’s.
CEO John Tague purchased 50,000 shares for about $900,000, with Chief Information Officer Tyler Best and CFO Thomas Kennedy purchasing $502,000 and $456,000 worth of shares respectively.
The move came less than a week after the car rental company stated second quarter revenue that declined 5% as a stronger dollar and weaker car rental volume took its toll on the company’s top line.
The company declared that it closed about 200 stores at off-airport locations in the quarter as it looks to save $300 million by March.
Hertz Global Holdings, Inc., through its auxiliaries, rents and leases cars and trucks in the United States and internationally. It operates in four segments: U.S. Car Rental, International Car Rental, Worldwide Equipment Rental, and All Other Operations.
Finally, Teladoc Inc(NYSE:TDOC), ended its last trade with -5.12% loss, and closed at $26.85.
Teladoc Inc, declared results for its second quarter ended June 30, 2015.
Jason Gorevic, Chief Executive of Officer of Teladoc, commented, “We saw strong performance during our first quarter as a public company. Our revenue was up substantially and we practiced noteworthy growth in both our membership base and in our number of visits.”
Financial Performance for the Three Months Ended June 30, 2015
- All comparisons, unless otherwise noted, are to the quarter ended June 30, 2014.
- Total revenue was $18.3 million, an enhance of 78%. Revenue from subscription access fees and visit fees was $15.1 million and $3.2 million, respectively, an enhance of 70% and 127%, respectively.
- Total membership was 11.5 million, contrast to 7.8 million, an enhance of 48%.
- Total visits were 125,322, contrast to 61,379, an enhance of 104%.
- Gross margin was 74%, contrast to a gross margin of 80%.
- Operating loss was $16.3 million, contrast to an operating loss of $2.9 million.
- Net loss per basic and diluted share was $7.20, contrast to a net loss per share of $2.15.
- EBITDA was a loss of $15.3 million, contrast to a loss of $2.3 million.
- Total cash, cash equivalents and marketable securities were $15.4 million at the end of the second quarter of 2015.
A reconciliation of GAAP to non-GAAP results has been offered in this press release in the accompanying tables. An explanation of these measures is also comprised of below under the heading “Non-GAAP Financial Measures”.
Teladoc, Inc. provides telehealth services via mobile devices, the Internet, video, and phone to clients and their customers in the United States. Its solution connects consumers with its physicians and behavioral health professionals who treat a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection, and sinusitis to dermatological conditions, anxiety, and smoking cessation.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
